portal
  Home About us Reports Charts News Custom Company Scan  
Report Charts News
*
Title Content
Economy&Goods
  Economy
  ConsumerGoods
  Food&Beverage
  Agriculture
Life Sciences
  Biotechnology
  Medical
  Pharmaceutical
Manufacturing
  Automotive
  Chemical
  Energy
  Machinery
  Material
  Metals & Minerals
Public Sector
  Environment
  Finance Service
  Infrastructure
  Logistics
  Real Estate
  Retailing
  Tourism
  Training
Technology And Media
  Electronics
  Internet
  Hardware
  Media
  Software
  Telecommunications

Tel: 0086-10-82600828
Fax: 0086-10-82601570
Email:


 The failure acquisition of Lijun Medical Equipment epitomises saturation of Chinese LargeVolume Parenteral market
 
CreateTime:2013-11-18 Editor:liaoyan
Text Size:       
 

Denied by Hongkong SEC, the acquisition deal of Lijun International Pharmaceutical from Kelun Group officially has being dropped today.

 China’s Kelun Group, Beijing Double-crane Pharmaceutical Co. and Lijun International Pharmaceutical account for over half of domestic LargeVolume Parenteral market. As the authority imposed GMP (Good Manufacturing Practice) and GSP( Good supply practice) policy, the entire medical device system is to embrace reshuffle. Also, the major medical device manufacturers face slowing growth speed. It is very obvious that the domestic LargeVolume Parenteral market is very saturated now. 


Related Reports
China Medical Robot Industry Report, 2020-2026
China Heparin Industry Report, 2015-2018
Global and China Stem Cell Industry Report, 2015-2018
China Medical Robot Industry Report, 2014-2018
2005-2021 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1